Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.

Learn More
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Drs. David Koren and T. Sam Albanesi Pen Article for Contagion Live about Lenacapavir for the Treatment of Multi-Drug Resistant HIV-1 Infection

View All News

David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA, Clinical Pharmacist Specialist in Infectious Diseases/HIV at Temple University Hospital (TUH), and T. Sam Albanesi, MD, Infectious Diseases Fellow at TUH, wrote an article for Contagion Live about lenacapavir, a new antiretroviral for the treatment of multi-drug resistant HIV-1 infection.